US EditionZydus Lifesciences receives Health Canada approval for smoking cessation drug - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Zydus Lifesciences receives Health Canada approval for smoking cessation drug - Express Pharma
Zydus Lifesciences, including its subsidiaries and affiliates (collectively referred to as “Zydus”), has received a Notice of Compliance (NOC) from Health Canada for its ZDS-Varenicline tablets in 0.5 mg and 1 mg strengths. This marks the company’s first NOC approval in Canada. Varenicline is indicated as an aid in smoking cessation. It functions as a partial nicotinic acetylcholine receptor agonist, which means it is designed to partially activ…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
